

Keystone Symposia in Victoria

Genome Engineering: From Mechanisms to Therapies

Fairmont Empress Victoria | Victoria, British Columbia, Canada | February 19–23, 2019

Scientific Organizers:

Andrew May, Chan Zuckerberg Biohub, USA

Rodolphe Barrangou, North Carolina State University, USA

Knut Woltjen, CiRA, Kyoto University, Japan



The use of programmable nucleases such as CRISPR-Cas systems, ZFNs and TALENs has revolutionized cell biology by providing the ability to manipulate specific genetic and epigenetic states within living cells. These systems have been broadly applied as tools in research settings and increasingly are being used to develop improved models of disease and engineer cells for therapeutic purposes. Together with other DNA-modifying systems such as recombinases, integrases and transposases, it is now possible to introduce mutations that will model human disease, build complex synthetic signaling networks to perform regulated functions, and design cells to target specific disease states. Improvements to the methods involved requires understanding enzyme structures and mechanisms and how they intersect with cellular DNA repair systems. The intersection of this basic science with engineering approaches and improved cellular models is revolutionizing our understanding and treatment of human disease. The goal of this Keystone Symposia conference is to bring together those developing and studying genome engineering tools with groups who are applying them to build new disease models, identify disease mechanisms and drug targets, and develop cell-based therapeutics and genetic medicines. In addition to covering engineering of human and animal cells, this conference will also highlight the emerging field of genome engineering to identify new anti-microbial and anti-viral drugs and applications toward next-generation antibiotics. Invited talks will explore a broad range of topics covering new technologies, fundamental basic research, through the development of screening approaches, stem cell-based models of disease and design, and development of cellular therapeutics.

Plenary Session Topics:

- Genome Engineering Tools and Technologies
- Workshop 1: Tools and Technologies
- Structure and Mechanism of Genome Editing Systems
- Engineered Models of Genetic Disease
- Workshop 2: Delivery
- Design and Engineering of Cellular Devices
- Genome Editing Screens for Function and Disease Mechanisms
- Harnessing DNA Repair Mechanisms for Genome Engineering
- Genome Engineering of Bacteria for Therapeutic and Diagnostic Applications
- Workshop 3: Clinical Trial Update
- Genome Editing for Treating Human Disease

Abstract Deadline: Nov 20, 2018; Discounted Registration Deadline: Dec 19, 2018

Visit www.keystonesymposia.org/19B4 for more details.



KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology
Accelerating Life Science Discovery
a 501(c)(3) nonprofit educational organization

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Genome Engineering: From Mechanisms to Therapies (B4)

February 19-23, 2019 • Fairmont Empress Victoria • Victoria, British Columbia, Canada

Scientific Organizers: Andrew May, Rodolphe Barrangou and Knut Woltjen

Sponsored by BlueRock Therapeutics, Editas Medicine and Thermo Fisher Scientific Inc.

Abstract & Scholarship Deadline: October 23, 2018 / Abstract Deadline: November 20, 2018 / Discounted Registration Deadline: December 19, 2018

TUESDAY, FEBRUARY 19

Arrival and Registration

WEDNESDAY, FEBRUARY 20

Welcome and Keynote Address

Philip D. Gregory, Bluebird Bio, USA
Talk Title to be Announced

Genome Engineering Tools and Technologies

Prashant Mali, University of California, San Diego, USA
Therapeutic Strategies via Genome Engineering: New Approaches and New Challenges

Zoltan Ivics, Paul Ehrlich Institute, Germany
Transposons: Molecular Parasites Tamed for Advanced Genome Engineering

Alexis C. Komor, University of California, San Diego, USA
Early Career Talk: Using Uracil as a Genome Editing Intermediate
Short Talk(s) Chosen from Abstracts

Workshop 1: Tools and Technologies

Short Talks Chosen from Abstracts

Structure and Mechanism of Genome Editing Systems

Benjamin P. Kleinstiver, Massachusetts General Hospital, USA
Engineered CRISPR Nucleases to Enhance Genome Editing

Andrew May, Chan Zuckerberg Biohub, USA
DNA Repair Outcomes Provide Insight into Genome Editing Mechanisms in Primary Cell Systems

Osamu Nureki, University of Tokyo, Japan
Structure and Mechanism of RNA-Programmable Nucleases
Short Talk(s) Chosen from Abstracts

Poster Session 1

THURSDAY, FEBRUARY 21

Engineered Models of Genetic Disease

Danwei Huangfu, Memorial Sloan Kettering Cancer Institute, USA
Human Pluripotent Stem Cells as Models for Genetic Disease

Knut Woltjen, CiRA, Kyoto University, Japan
Isogenic Models of Disease from Induced Pluripotent Stem Cells

Amy J. Wagers, Harvard University, USA
Gene Editing in Stem Cells

Erika Sasaki, Central Institute for Experimental Animals, Japan
Talk Title to be Announced

Short Talk(s) Chosen from Abstracts

Poster Session 2

Workshop 2: Delivery Methods

Short Talks Chosen from Abstracts

Design and Engineering of Cellular Devices

Wilson Wong, Boston University, USA
Synthetic Biology in Cellular Immunotherapy

Timothy K. Lu, Massachusetts Institute of Technology, USA
Synthetic Gene Circuits for Next-Generation Therapeutics

Charles Gersbach, Duke University, USA
Cell Programming with Genome Engineering Technologies
Short Talk(s) Chosen from Abstracts

FRIDAY, FEBRUARY 22

Genome Editing Screens for Function and Disease Mechanisms

Fyodor D. Urnov, Altius Institute for Biomedical Sciences, USA
Editing Human Genome Control Circuits to Reveal Disease Mechanisms and Targets for Intervention in the Clinic

Jan E. Carette, Stanford University, USA
CRISPR-Cas Screens for Studying Virus-Host Interactions
Speaker to be Announced

Brittany Adamson, University of California, San Francisco, USA
Early Career Talk: Perturb-Seq: Combining High throughput CRISPR Screening with Single-Cell Sequencing
Short Talk(s) Chosen from Abstracts

Harnessing DNA Repair Mechanisms for Genome Engineering

Maria Jasin, Memorial Sloan Kettering Cancer Center, USA
Homologous Recombination and End-Joining Mechanisms in Genome Editing

Beeke Wienert, UC Berkeley, USA
Unbiased Identification of CRISPR Off Targets in vivo using DISCOVER-seq

Nancy Maizels, University of Washington School of Medicine, USA
Gene Correction at Targeted DNA Breaks
Short Talk(s) Chosen from Abstracts

Poster Session 3

SATURDAY, FEBRUARY 23

Genome Engineering of Bacteria for Therapeutic and Diagnostic Applications

Rodolphe Barrangou, North Carolina State University, USA
Engineered Lactobacilli for Human Health Applications

Jason M. Peters, University of Wisconsin-Madison, USA
Bacterial CRISPRi Screens to Identify the Mode of Action of Novel Antibiotics

Richard P. Novick, New York University, USA
Conversion of Staphylococcal Pathogenicity Islands (SaPIs) to CRISPR-Cas9-Carrying Antibacterial Drones That Cure Staphylococcal Infections

Short Talk(s) Chosen from Abstracts

Workshop 3: Clinical Development Progress

Short Talks Chosen from Abstracts

Genome Editing for Treating Human Disease

Bruce R. Conklin, Gladstone Institutes, USA
Genome Surgery for Treating Neuronal Disorders

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Genome Engineering: From Mechanisms to Therapies (B4)

February 19-23, 2019 • Fairmont Empress Victoria • Victoria, British Columbia, Canada

Scientific Organizers: Andrew May, Rodolphe Barrangou and Knut Woltjen

Sponsored by BlueRock Therapeutics, Editas Medicine and Thermo Fisher Scientific Inc.

Abstract & Scholarship Deadline: October 23, 2018 / Abstract Deadline: November 20, 2018 / Discounted Registration Deadline: December 19, 2018

Paula M. Cannon, University of Southern California, Keck School of Medicine, USA

Genome Editing to Treat Hematopoietic Disorders and Infectious Diseases

Michel Sadelain, Memorial Sloan Kettering Cancer Center, USA

Genome Edited CAR-T Cells for Improved Treatment of Solid Tumors

Juan Carlos Izpisua-Belmonte, The Salk Institute for Biological Studies, USA

Engineering Stem Cells in vivo for Therapeutic Benefit

Short Talk Chosen from Abstracts

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

SUNDAY, FEBRUARY 24

Departure